NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Drug Manufacturers - General · USD

Bristol-Myers Squibb Company (BMY) Stock Analysis

Bristol-Myers Squibb Company (BMY) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

BMY

$61.12

−$0.56 (−0.91%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BMY with… →

BMY Key Statistics

As of Oct 21, 2026
Trading
Open
$61.50
Previous Close
$61.68
Day's Range
60.69–61.81
52-Week Range
42.52–68.64
Volume
9.02M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.18
Valuation
Market Cap
$124.85B
P/E Ratio
13.46
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.25
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
17.17
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.54
EPS (ttm)Profit attributable to each share over the last twelve months.
4.54
Financials (FY)
Revenue (FY)
$48.20B−0.22%
Net Income (FY)
$7.05B
Profit marginThe share of revenue left as profit after all costs and taxes.
18.87%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.04B
1-Year Return
+43.33%
Dividend and dates
Dividend
$2.52+4.09%
Ex-Dividend Date
October 2, 2026
Earnings Date
October 29, 2026
Avg Volume
11.67M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BMY closed at $61.12, +43.33% over 1 year.

Bristol-Myers Squibb Company (BMY) has a market capitalization of $124.85B.

In fiscal 2025, BMY reported revenue of $48.20B.

BMY Stock Return by Calendar Year

Bristol-Myers Squibb Company (BMY) 10-year return: what $10,000 became

1 year
$10,000 $14,333
+43.33%
5 years
$10,000 $13,004
+30.04%
10 years
$10,000 $17,439
+74.39%

If you had invested $10,000 in Bristol-Myers Squibb Company (BMY) 10 years ago, at the close on October 21, 2016, it would have been worth $17,439 at the close on October 21, 2026: +74.39% in total, +5.72% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+18.35%
2025+0.11%
2024+15.81%
2023−26.14%
2022+18.98%
2021+2.88%
2020+0.41%
2019+27.74%
2018−12.90%
2017+7.71%
2016 (partial year)−3.41%

As of October 21, 2026.

BMY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$48.20B$7.05B14.6%
2024$48.30B−$8.95B−18.5%
2023$45.01B$8.03B17.8%
2022$46.16B$6.33B13.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$48.20B$34.26B$13.72B$7.05B14.6%
2024$48.30B$34.33B$5.89B−$8.95B−18.5%
2023$45.01B$34.31B$8.20B$8.03B17.8%
2022$46.16B$36.02B$9.10B$6.33B13.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BMY Dividend History

$2.48+3.3% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$2.524—
2025$2.484+3.3%
2024$2.404+5.3%
2023$2.284+5.6%
YearDividends per sharePaymentsChange
2026 (partial year)$2.524—
2025$2.484+3.3%
2024$2.404+5.3%
2023$2.284+5.6%
2022$2.164+46.9%
2021$1.473−35.8%
2020$2.295+39.6%
2019$1.644+2.5%
2018$1.604+2.6%
2017$1.564—

Most recent payment: $0.63 per share, ex-dividend October 2, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

BMY Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricBMYDrug Manufacturers - General medianvs median
P/E13.4625.2347% below
P/S ratio2.543.2321% below
Profit margin18.87%9.80%9.1 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bristol-Myers Squibb Company (BMY) is capitalised at $124.85B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - General industry. The company reports 32,500 employees.

BMY last closed at $61.12 on October 21, 2026. That is −$0.56 (−0.91%) against the previous close. Over the past 52 weeks the price has ranged from $42.52 to $68.64. The latest close sits 43.74% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $48.20B. Against the prior fiscal year total of $48.30B, that is a change of −0.22%. Net income for the same year was $7.05B. Profit margin runs at 18.87%. That is 9.1 percentage points above the Drug Manufacturers - General median of 9.8%. Earnings per share on a trailing basis come to 4.54.

Across the 4 fiscal years on file, revenue moves from $46.16B in 2022 to $48.20B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

BMY trades at a trailing price-to-earnings ratio of 13.46. That is 46.65% below the Drug Manufacturers - General median of 25.23. On forward earnings the ratio is 9.25. The PEG ratio, which sets the P/E against expected earnings growth, reads 17.17. The price-to-sales ratio is 2.54. On price-to-sales that is 21.39% below the Drug Manufacturers - General median of 3.23. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +43.33%. Measured over 10 years, that is +5.72% a year compounded. The reported beta is 0.18. Daily returns over the trailing 10 years annualize to a volatility of 24.91%.

Growth & Income

The trailing dividend yield is 4.09%. That is 1.8 percentage points above the Drug Manufacturers - General median yield of 2.3%. At the indicated rate that is $2.52 a share a year. The ex-dividend date on file is October 2, 2026. Dividends are recorded for 10 calendar years; 2026 shows 4 payments totalling $2.52 a share. The year before, 2025, totalled $2.48 a share.

The strongest complete calendar year on file is 2019 at +27.74%; the weakest is 2023 at −26.14%. Of the 9 complete calendar years on file, 7 finished higher. So far in 2026 the total return is +18.35%.

Peer Comparison

Bristol-Myers Squibb Company (BMY) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bristol-Myers Squibb Company BMY $124.85B 13.5
Eli Lilly and Company LLY $1.13T 42.7
Johnson & Johnson JNJ $621.22B 39.1
AbbVie Inc. ABBV $503.27B 80.5

The Drug Manufacturers - General industry average P/E ratio is 25.2x. Bristol-Myers Squibb Company trades at a P/E of 13.5.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 MRK

Merck & Co., Inc.

$369.78B

 NVS

Novartis AG

$292.58B

 AZN

AstraZeneca PLC

$261.82B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$374.30B

 TMO

Thermo Fisher Scientific Inc.

$256.61B

 AMGN

Amgen Inc.

$236.98B

 GILD

Gilead Sciences, Inc.

$190.42B

 ABT

Abbott Laboratories

$173.92B
View all Healthcare stocks →

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Visit website →